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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYTranscription-factor-induced somatic cell conversions are highly relevant for both basic and clinical research yet their mechanism is not
fully understood and it is unclear whether they reflect normal differentiation processes. Here we show that during pre-B-cell-to-macro-
phage transdifferentiation, C/EBPa binds to two types of myeloid enhancers in B cells: pre-existing enhancers that are bound by PU.1,
providing a platform for incoming C/EBPa; and de novo enhancers that are targeted by C/EBPa, acting as a pioneer factor for subsequent
binding by PU.1. The order of factor binding dictates the upregulation kinetics of nearby genes. Pre-existing enhancers are broadly active
throughout the hematopoietic lineage tree, including B cells. In contrast, de novo enhancers are silent in most cell types except in
myeloid cells where they become activated by C/EBP factors. Our data suggest that C/EBPa recapitulates physiological developmental
processes by short-circuiting two macrophage enhancer pathways in pre-B cells.INTRODUCTION
The discovery that transcription factors (TFs) can convert
somatic cells into both specialized and induced pluripotent
stem cells (iPSCs) has revolutionized stem cell research and
promises to have major clinical applications (Graf and
Enver, 2009; Yamanaka and Blau, 2010). Lineage-instruc-
tive TFs activate and repress tissue-specific genes by recog-
nizing sequence-specific DNA consensus motifs contained
within enhancers and promoters (Ptashne, 2007). They
establish gene regulatory networks (GRNs) of the novel
gene expression program while dismantling those of the
old program, involving the formation of feedforward,
cross-inhibitory, and auto-regulatory loops (Bertrand and
Hobert, 2010; Davidson, 2010; Graf and Enver, 2009;
Holmberg and Perlmann, 2012). However, how these pro-
cesses are coordinated and whether they recapitulate
normal development remain unclear (Vierbuchen and
Wernig, 2011), especially as neither TF-induced lineage
conversions nor iPSC reprogramming appear to retrace
normal developmental pathways (Apostolou and Hoched-
linger, 2013; Di Tullio et al., 2011; Ladewig et al., 2013;
Vierbuchen and Wernig, 2011).
Lineage-instructive TFs act through synergistic and cross-
antagonistic interactions, are typically able to access closed
chromatin (Zaret and Carroll, 2011), preferentially target
sites with specific histone mark combinations, and bind
to either nucleosome-depleted or nucleosome-dense re-232 Stem Cell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The Autgions (Soufi et al., 2012; Taberlay et al., 2011; Wapinski
et al., 2013). However, what establishes these chromatin
configurations in the first place and what proportion of
the incoming reprogramming factors interacts with pre-
existing TF complexes are largely unknown. Amajor reason
for these gaps in our knowledge is that cell conversion fre-
quencies in most cell systems are low, complicating efforts
to study early events in a time-resolved fashion.
An exception is the transdifferentiation of pre-B/B cells
into macrophages induced by the leucine zipper-type TF
C/EBPa, which is arguably the most efficient and rapid sys-
tem described so far (Bussmann et al., 2009; Di Tullio and
Graf, 2012; Xie et al., 2004). C/EBPb, like C/EBPa, can like-
wise induce B cell transdifferentiation into macrophages
(Bussmann et al., 2009; Xie et al., 2004), but the two factors
also have non-redundant functions. Mice ablated for
C/EBPa die shortly after birth because they lack granulo-
cyte/macrophage progenitors (GMPs, precursors of neutro-
phil granulocytes and macrophages, two closely related
myeloid cell types) as well as granulocytes, while C/EBPb-
knockout animals are fully viable but containmacrophages
and B cells with functional defects (Chen et al., 1997;
Tanaka et al., 1995). C/EBPa cooperates with PU.1 (Spi1)
to regulate myeloid gene expression (Friedman, 2007), the
two factors interact physically (Reddy et al., 2002), and a
combination of C/EBPa and PU.1 converts fibroblast into
macrophage-like cells (Feng et al., 2008). The Pu.1 gene en-
codes an Ets family TF specifically expressed in the earlyhors
stages of hematopoiesis and its knockout generates mice
that lack both myeloid and lymphoid cells (Scott et al.,
1994). Low-level expression of PU.1 in hematopoietic pre-
cursors induces B cell differentiation, whereas high levels
favor myeloid differentiation (DeKoter and Singh, 2000).
Here we have analyzed, in a time-resolved manner, how
C/EBPa establishes a myeloid expression program in pre-B
cells, and we found that it binds to both pre-existing en-
hancers occupied by PU.1 and de novo enhancers where
it acts as a pioneer factor. Strikingly, the combined activa-
tion of these enhancer types, regulating the expression of
nearby macrophage genes, recapitulates the activation of
myeloid enhancers and associated genes during normal
hematopoiesis.RESULTS
C/EBPa Induces High-Level Expression of Pu.1
and Cebpb
To study howC/EBPa induces transdifferentiation, we used
two pre-B cell lines that express an inducible C/EBPaER
fusion protein tagged with either human CD4 (hCD4;
C11 cells) or GFP (C10 cells). In both lines, treatment
with 17 beta-estradiol (b-Est) shuttles C/EBPaER into the
nucleus and induces the formation of macrophage-like
cells within 2 to 3 days (Bussmann et al., 2009). Impor-
tantly, C/EBPamRNA levels in C10 cells at 0 hr post-induc-
tion (hpi) or 24 hpi did not exceed C/EBPa levels observed
in primary macrophages (MF) (Figure S1A). To monitor
two important myeloid regulators known to cooperate
with C/EBPa, we tested the expression levels of Cebpb and
Pu.1. These genes were expressed at low to intermediate
levels in pre-B cells (Figure S1B) and became upregulated
within 3–12 hpi (Figure 1A). As C10 cells become transgene
independent 24 hpi (Bussmann et al., 2009), i.e., before the
expression of endogenous C/EBPa (Figure 1A), we deter-
mined whether the rapid activation of C/EBPb and PU.1
is necessary for transdifferentiation. We generated C11
cells stably expressing a short hairpin RNA (shRNA) against
C/EBPb, PU.1, or both. Cells were induced with b-Est and
analyzed by fluorescence-activated cell sorting (FACS) for
the presence of Cd19 and Mac-1 (CD11b) at different
days thereafter. At 3 days post-induction (dpi), the knock-
down of C/EBPb and of PU.1 resulted in a 35% and 50%
reduction in the formation of Mac-1+Cd19 cells, respec-
tively, while deleting both factors further enhanced the
effect. At 7 dpi, Mac-1 expression in shC/EBPb cells caught
up with wild-type levels, whereas cells expressing shPU.1
exhibited extensive cell death (Figures 1B and S1C). These
data show that C/EBPa rapidly upregulates Pu.1 and Cebpb,
that PU.1 is necessary to establish the myeloid GRN, and
that C/EBPb plays a more minor role.Stem CA Limited Set of Sites Stably Bound by C/EBPa
Correlates with the Upregulation of Macrophage
Genes
To explore the mechanism by which C/EBPa turns on the
myeloid program in pre-B cells, we treated C10 cells for
different times with b-Est and performed chromatin immu-
noprecipitation followed by deep sequencing (ChIP-seq)
experiments, using antibodies to C/EBPa, C/EBPb, and
PU.1 (Table S1 gives a summary of ChIP-seq results and
peak calling). A total of 54,198 non-redundant C/EBPa-
enriched regions could be detected during the time course
of which 10,849 sites were stably bound (i.e., up to 48 hpi,
Table S2), whereas the remaining sites were transiently
bound. Genes nearest stable binding sites, but not tran-
sient sites, were enriched for upregulated genes (Fig-
ure S1D). In addition, using a sliding-window approach,
we observed that 70% of upregulated genes were localized
within 100 kb of a stable C/EBPa-binding site, whereas no
such enrichment was seen for downregulated genes (Fig-
ure 1C). Motif analysis of the stable sites in 48-hpi cells
(hereafter referred to as induced macrophages or iMF)
showed strong enrichment for consensus motifs of C/EBP
and PU.1. The same sites also were enriched for AP-1 (Jun
and Fos) and RUNX motifs, as previously reported (Fig-
ure 1D; Heinz et al., 2010) and more weakly enriched for
EBF1 (Figure 1D; also see Figure 3). The majority of stable
C/EBPa sites were co-occupied by C/EBPb and PU.1 in
iMF, and 40% of these were pre-bound by PU.1 in pre-
B cells, however, showing lower intensity signals (Fig-
ure 1E). Low-intensity signals in pre-B cells also were
detectable for C/EBPb, reflecting its low-level expression,
as well as for C/EBPa (Figure S1E), suggesting some leaki-
ness of the transgene.
A total of 10,849 C/EBPa sites were detected in iMF and
62,814 in bone-marrow-derivedmacrophages (MF) (Zhang
et al., 2013), showing 9,288 common sites (Figure 1F). The
larger number of sites in MF compared to iMF cannot be
explained by a higher sequencing depth (Table S1). How-
ever, these differences became smaller when the numbers
of associated genes were compared as follows: C/EBPa sites
combined with 5,849 and 14,078 genes in iMF and MF,
respectively, and shared 5,252 genes (Figure S1F). The
shared gene set was enriched for genes that became upregu-
lated during transdifferentiation of primary B cells into
macrophages (Di Tullio et al., 2011), whereas the gene set
unique for MF (8,826) was actually depleted (Figure S1G).
In addition, shared upregulated genes were enriched for
gene ontology (GO) terms associated with myeloid func-
tion, while upregulated genes unique for MFwere not (Fig-
ure S1H). The induced rapid and efficient conversion of
pre-B cells into highly motile, aggregating, and phagocytic
macrophages within 51 hr (Movie S1; Bussmann et al.,
2009) further supports the interpretation that C/EBPaell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The Authors 233
(legend on next page)
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binds to a core set of enhancers in iMF required formyeloid
cell specification.
The binding of C/EBPa, C/EBPb, and PU.1 in induced
C10 cells and of C/EBPa in primary MF is illustrated for
the promoter and the 14-kb URE enhancer of the Pu.1
gene (Yeamans et al., 2007), for three putative enhancers
of Cebpb (Figure 1G), as well as for putative enhancers of
Fos and Il1b (Figure S1I). (Genomic coordinates of these
and other regions are described in Table S3.) Together, our
data suggest that C/EBPa combined with C/EBPb and
PU.1 activates a core set of enhancers, shared between
the cell line and primary macrophages, required to induce
macrophage specification.
Prospective Myeloid Enhancers in Pre-B Cells Fall into
Two Broad Classes
To characterize the epigenetic status of prospectivemyeloid
regulatory regions in pre-B cells, we performed ChIP-seq
experiments for histone modifications characteristic of
poised (H3K4Me1), active (H3K27Ac, P300), and repressed
enhancers (H3K27Me3) (Creyghton et al., 2010; Rada-Igle-
sias et al., 2011), and we analyzed levels of these marks at
C/EBPa sites away from the transcription start site (TSS),
representing putative enhancers (Figure S2A). We observed
two broad classes of prospective myeloid enhancers in pre-
B cells as follows: (1) pre-existing enhancers that were deco-
rated with H3K4Me1, H3K27Ac, and P300 and depleted for
H3K27Me3 (Figure 2A); and (2) de novo enhancers that
lacked any of the active enhancer marks but were instead
often decorated with H3K27Me3 (Figure 2A). Similar re-
sults were obtained by performing ChromHMM analysis
(Figure S2C; Ernst and Kellis, 2012) as an independent
analytical approach demonstrating that pre-existing en-
hancers are enriched for activation marks, whereas de
novo enhancers are depleted for activation marks and en-
riched for H3K27Me3 (Figure S2D). Approximately two-
thirds of the pre-existing enhancers were bound by PU.1
and exhibited high levels of activation marks compared
to sites not bound by PU.1 (Figure S2B). Importantly, we
confirmed the presence of pre-existing- and de-novo-typeFigure 1. Upregulation of Cebpb and Pu.1 Genes by C/EBPa and E
(A) Expression of endogenous Pu.1, Cebpb, and Cebpa RNA after b-Est
as mean ± SEM (independent triplicates) expressed as the fold induc
(B) FACS plots of C11 pre-B cell carrying either a scrambled short ha
PU.1, or both, and induced by b-est treatment. See also Figure S1C.
(C) Percentage of upregulated or downregulated genes (>2-fold) with
70% of all upregulated genes are within 100 kb of a C/EBPa-binding
(D) Significantly enriched sequence motifs at C/EBPa-binding sites a
(E) Heatmaps visualizing C/EBPa, C/EBPb, and PU.1 binding in pre-B
(F) Venn diagram showing the intersection of C/EBPa sites in iMF (n
(G) Screenshots of C/EBPa, C/EBPb, and PU.1 binding at selected enha
length of ORF, and direction of transcription. See also Figure S1I.
Stem Cenhancers in primary B cells by using recently published
ChIP-seq datasets (Figure 2B; Heinz et al., 2010; Lara-
Astiaso et al., 2014). Furthermore, we confirmed binding
of C/EBPa to selected pre-existing enhancers of the Pu.1,
Cebpb, Il1b, Ehd1, and Ifngr2 genes and to de novo en-
hancers of the Mmp12, Cd14, Gbe1, Fos, and Fgd4 genes
in primary pre-B cells induced to transdifferentiate (Figures
2C and 2D; Di Stefano et al., 2014).
To determine whether the enhancer activation state in
pre-B cells correlates with gene expression, we first
analyzed the promoter configuration of adjacent genes
and found the following: 73% of the pre-existing en-
hancers paired with active promoters (as defined by the
sole presence of H3K4Me3), 7% were decorated with inac-
tive promoters (H3K27Me3 or no marks), and 20% were
decorated with promoters containing a bivalent domain
(H3K4Me3 and H3K27Me3) (Figure 2E). In contrast, only
36% of de novo enhancers paired with active promoters,
44% with inactive promoters, and 20% with bivalent pro-
moters (Figures 2E and S2E). Based on these results, we re-
defined pre-existing enhancers as those that combine
with active promoters and de novo enhancers as those
that pair with inactive promoters. As expected, genes asso-
ciated with pre-existing enhancers already were expressed
at significant levels in pre-B cells and primary pre-B cells
(Bussmann et al., 2009; Di Tullio et al., 2011), whereas
genes associated with de novo enhancers only showed
background expression levels (Figure 2F).
The finding that pre-B cells express genes associated
with pre-existing enhancers predicts that PU.1 expression
in cells devoid of PU.1 will selectively activate these genes.
To test this, we expressed PU.1 in 3T3 fibroblasts (Figure
2G) and measured mRNA levels of a number of genes
associated with either pre-existing or de novo enhancers.
Supporting the hypothesis that PU.1 preferentially
binds to pre-existing enhancers and activates associated
genes, we observed that 6 of 11 pre-existing enhancer-
associated genes tested were upregulated as compared to
2 of 10 de novo genes (Figure 2G; primer sequences are in
Table S4).ffects of Their Knockdown on Transdifferentiation
induction of C10 cells as measured by qRT-PCR. Data are represented
tion relative to uninduced pre-B cells.
irpin knockdown construct (control) or constructs against C/EBPb,
in defined windows around C/EBPa sites. Dotted lines indicate that
site.
s determined by HOMER.
cells and iMF. Window, 3 kb; bin, 10 bp. See also Figure S1E.
= 10,849) and primary MF (n = 62,814).
ncers in C10 cells and of C/EBPa in primary MF. Arrows indicate TSS,
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Figure 2. Prospective Myeloid Enhancers with Either Pre-existing or De Novo Configurations in Pre-B Cells
(A) Heatmaps visualizing H3K4Me1, H3K27Ac, P300, H3K27Me3, and PU.1 in pre-B cells and C/EBPa binding in iMF. Center of C/EBPa
binding, 0; window, 6 kb; bin, 100. See also Figures S2B–S2D.
(B) As in (A), visualizing H3K4Me1, H3K27Ac, and PU.1 in primary mature B cells.
(C and D) Screenshots of C/EBPa and PU.1 binding in C10 cells (0 and 48 hpi) and primary pre-B cells (0 and 18 hpi) at pre-existing (C) and
de novo enhancers (D).
(E) Distribution of genes nearest pre-existing or de novo enhancers marked with bivalent (H3K4Me3, H3K27Me3), active (H3K4Me3), or
repressed (H3K27Me3 or no marks) promoters. See also Figure S2E.
(legend continued on next page)
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Together, our findings suggest that C/EBPa is capable of
activating two broad classes of prospective myeloid en-
hancers in pre-B cells as follows: (1) pre-existing enhancers
with active enhancer marks that are predominantly associ-
ated with expressed genes, and (2) de novo enhancers lack-
ing such marks that are predominantly associated with
silenced genes.
A Subset of Pre-existing Myeloid Enhancers Is Bound
by the B Cell TF Ebf1 in Pre-B Cells
Ourfinding thatmotifs associatedwith theB cell TFEbf1 are
enriched inmyeloid enhancers (see Figure 1D) prompted us
to study their relevance in transdifferentiation. Analysis of
the Ebf1 motif distribution shows that it is specifically en-
riched in pre-existing enhancers (Figure 3A). To test actual
binding of Ebf1, we performed ChIP-seq experiments in
pre-B cells yielding 6,627 Ebf1 peaks that were predomi-
nantly located in intergenic regions (Figure 3B) and en-
riched for EBF1, ETS (PU.1), and E2A motifs (Figure 3C).
In line with the motif analysis, intersection of Ebf1-bound
sites with the two types of myeloid enhancers showed 725
that were associated with pre-existing enhancers, but virtu-
ally none with de novo enhancers (Figure 3D).
To determine the functional state of the Ebf1-bound en-
hancers targeted by C/EBPa, we determined the kinetics of
Ebf1 and C/EBPa binding as well as H3K27Ac decoration
after induction of transdifferentiation. The heatmaps in
Figure 3E show that, while C/EBPa binding already was
observed after 3 hpi, the loss of Ebf1 binding was not de-
tected until 48 hpi. However, H3K27Ac enrichment at
these enhancers was maintained throughout the time
course (Figure 3E), suggesting that the relevant enhancers
remain active even after the loss of Ebf1. Examples of
enhancers bound by Ebf1, C/EBPa, and PU.1 are shown
in Figure 3F. This includes the 88-kb putative enhancer
of Cebpb (see Figure 1G), as well as Nfe2 and Cd40
enhancers. In addition to enhancers bound by Ebf1,
C/EBPa, and PU.1, 27% lack PU.1 binding, as exemplified
by the 150-kb Tgfbr2 putative enhancer (Figure 3F; addi-
tional examples are shown in Figure S3A). Ebf1 binding
to these regions was confirmed using an independent
Ebf1 ChIP-seq dataset (Treiber et al., 2010; Figures S3B
and S3C). Importantly, genes associated with putative
Ebf1-C/EBPa-bound enhancers were upregulated during
transdifferentiation (Figure S3D).
In conclusion, a significant proportion of pre-existing
myeloid enhancers targeted by C/EBPa in pre-B cells are(F) Distribution of mRNA levels of upregulated genes nearest to either
(C10) and primary pre-B cells. Statistical analysis by Wilcoxon rank-s
(G) Expression of genes nearest pre-existing or de novo enhancers in 3T
as mean ± SEM (independent triplicates) and expressed as the fold ind
*p < 0.05.
Stem Cbound by the B cell TF Ebf1. This finding raises the possibil-
ity that pre-existing myeloid enhancers act as bona fide B
cell enhancers and that C/EBPa converts them into en-
hancers active in myeloid cells.
C/EBPa Acts Both as a Pioneer and as a Secondary
Factor at Prospective Myeloid Enhancers
To study how the two enhancer types become activated, we
determined the binding kinetics of PU.1, C/EBPa, and
C/EBPb. As expected, at pre-existing enhancers PU.1 was
bound throughout the time course, whereas it was initially
absent at de novo enhancers, gradually increasing after in-
duction (Figures 4A and S4A). In contrast, C/EBPa binding
showed a steeper increase at pre-existing than at de novo
enhancers, with both converging at 48 hpi and the rate
of C/EBPa binding kinetics correlating with the starting
levels of H3K27Ac or H3K27Me3, respectively (Figure S4B).
Finally, C/EBPb occupancy increased steadily at the two
enhancer types (Figures 4A and S4A).
The binding profiles observed predict that at de novo en-
hancers C/EBPa binds before PU.1. Indeed, ChIP-seq exper-
iments with induced C10 cells at early time points (10, 30,
and 60 min post-induction) showed that C/EBPa binds to
74% of de novo sites before PU.1 (Figure 4B). An example
of a putative pre-existing enhancer bound by PU.1 first is
shown for the Tyrobp gene; examples of de novo enhancers
are the 24-kb site of Tlr4, the 65-kb enhancer of Cebpb, and
the 16-kb site of Ctsd (Figure 4C).
To further study the interplay between PU.1 and C/EBPa,
we knocked down PU.1 in pre-B cells (Figure S4C), induced
transdifferentiation for 3 and 24 hr, and analyzed C/EBPa
binding at five pre-existing and five de novo enhancers.
In control cells we observed higher binding of C/EBPa at
3 hpi for the pre-existing relative to the de novo enhancers.
In addition, knockdown of PU.1 caused an initial decrease
of C/EBPa binding at 3 hpi for both enhancer types on all
loci tested (Figures 4D and 4E; primer sequences are in
Table S4). However, at 24 hpi, C/EBPa binding recovered
to control levels or even above in 9 of 10 enhancers tested
(Figures 4D and 4E). This suggests that C/EBPa binding at
pre-existing enhancers does not strictly require PU.1,
raising the possibility that C/EBPa can access closed chro-
matin (see also Figures 2A and S4B).
To test this more directly, we performed micrococcal
nuclease (Mnase) digestion experiments with chromatin
isolated from pre-B cells and iMF cells and deep-sequenced
nuclease-protected DNA. Average nucleosome profilespre-existing (n = 318) or de novo (n = 103) enhancers in pre-B cells
um test, **p < 0.001.
3 cells or 3T3 overexpressing PU.1 by qRT-PCR. Data are represented
uction relative to 3T3 cells. Statistical analysis by Student’s t test,
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Figure 3. Binding of the B Cell TF Ebf1 to
Pre-existing Enhancers
(A) Frequency of Ebf1 motif within pre-ex-
isting and de novo C/EBPa-binding sites by
HOMER.
(B) Genomic distribution of Ebf1-binding
events (n = 6,627) relative to the TSS in C10
cells. ORF, open reading frame.
(C) Significantly enriched sequence motifs
at Ebf1-binding sites, as determined by
HOMER.
(D) Number of C/EBPa sites bound by Ebf1
for each enhancer type.
(E) Heatmaps, centered on C/EBPa binding
in iMF, visualizing Ebf1, C/EBPa, and
H3K27Ac after the induction of trans-
differentiation. Center of binding, 0; win-
dow, 6 kb; bin, 100.
(F) Screenshots of C/EBPa, PU.1, Ebf1, and
H3K27Ac ChIP-seq profiles at selected
enhancer regions in C10 cells. See also
Figures S3A–S3D.calibrated with sites uniquely bound by PU.1 revealed a
nucleosome-depleted region (valley) flanked by two posi-
tioned nucleosomes (Figure S4D) that confirmed an earlier
report (Heinz et al., 2010). Pre-existing enhancers bound by238 Stem Cell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The AutPU.1 in pre-B cells showed a small valley that becamemore
pronounced in iMF (Figure 4F). In contrast, de novo en-
hancers targeted by C/EBPa in pre-B cells were contained
in a nucleosome-dense region that changed into a profilehors
Figure 4. C/EBPa Binds to Open and
Closed Chromatin
(A) Kinetics of PU.1, C/EBPa, and C/EBPb
binding at center position of pre-existing
(n = 4,711) and de novo (n = 3,424) en-
hancers at indicated hpi. Statistical anal-
ysis by Wilcoxon rank-sum test, **p <
0.001. See also Figures S4A and S4B.
(B) C/EBPa and PU.1 binding order on
de novo sites (C/EBPa first [C/EBPa-PU.1],
simultaneously, or PU.1 first [PU.1-
C/EBPa].
(C) Screenshots of C/EBPa and PU.1 binding
at selected pre-existing or de novo en-
hancers (10, 30, and 60 min).
(D and E) C/EBPa binding at pre-existing
(D) or de novo (E) enhancers in induced C10
cells knocked down for PU.1. See also Fig-
ure S4C. Data are represented as mean ±
SEM (independent triplicates). Statistical
analysis by Student’s t test, *p < 0.05.
Primer sequences are given in Table S4.
(F and G) Average MNase profiles at pre-
existing (F) and de novo (G) enhancers
bound by C/EBPa and PU.1 (shown in blue
and brown). Profiles were centered on PU.1
binding in iMF and normalized by median
subtraction. Window, 6 kb; bin, 1 bp. See
also Figures S4D and S4E.
Stem Cell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The Authors 239
similar to that observed for pre-existing enhancers,
although less pronounced, in iMF (Figure 4G). No ordered
nucleosome patterns were obtained with profiles centered
on random genomic positions (Figure S4E).
Our data show that C/EBPa binds to a nucleosome-
depleted region in pre-existing enhancers and to a nucleo-
some-dense region in de novo enhancers. These findings
support the notion that C/EBPa can act as a pioneer factor.
The C/EBPa and PU.1 Binding Order Determines the
Activation Kinetics of Adjacent Genes
To determine whether the epigenetic status of the two
enhancer types in pre-B cells influences their subsequent
activation kinetics, we analyzed enrichment levels of
H3K4Me1, H3K27Ac, P300, and H3K27Me3 during trans-
differentiation. As judged by P300 and H3K27Ac, pre-exist-
ing enhancers became hyper-activated, albeit mostly in a
transient manner. In contrast, de novo enhancers became
gradually activated, starting from background levels (Fig-
ures 5A, 5B, and S5A). Both enhancer types followed a
similar sequence of enhancer mark acquisition, consisting
in P300 binding followed by H3K4Me1 and H3K27Ac
decoration (Figure 5B). In contrast, the repressive
H3K27Me3 decreased, predominantly on de novo en-
hancers (Figures 5C and S5B). These findings are illustrated
for the pre-existing 3-kb FIRE enhancer of the Csf1r gene
and the de novo 16-kb enhancer of Ctsd (Figure 5D).
Additional examples are shown in Figure S5C.
To determine how the two types of prospective myeloid
enhancers modulate the upregulation kinetics of adjacent
genes, we interrogated gene expression data from C10 cells
and primary pre-B cells induced to transdifferentiate (Buss-
mann et al., 2009; Di Tullio et al., 2011). Pre-existing
enhancer-associated genes started from low expression
levels and became gradually upregulated 4-fold, while
de novo enhancer-associated genes started from back-
ground levels and were upregulated 9-fold (Figures 5E,
5F, S5D, and S5E).
In sum, the C/EBPa and PU.1 binding order determines
the activation kinetics of targeted enhancers, with pre-ex-
isting enhancers becoming activated gradually fromdetect-
able base levels and de novo enhancers becoming activated
more steeply and with a delay. These differences also are re-
flected in the activation kinetics of adjacent genes.
Pre-existing and De Novo Enhancers Are in an Active
State in Distinct Hematopoietic Cell Types
Are the pre-existing and de novo myeloid enhancers iden-
tified during transdifferentiation relevant for normal he-
matopoietic differentiation? To study this we determined
their activation state in various types of immature and
mature hematopoietic cells and interrogated expression
data of associated genes during hematopoiesis (Lara-240 Stem Cell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The AutAstiaso et al., 2014; see Figure 6A for the hematopoietic
lineage tree and nomenclature used). Surprisingly, 58%
of pre-existing enhancers already were active (i.e., marked
by H3K27Ac) in long-term hematopoietic stem cells (LT-
HSCs), and their proportion further increased in common
myeloid and lymphoid progenitors (CMPs and CLPs,
respectively), reaching 66% and 74% in terminally
differentiated granulocytes (Gns) and MF, respectively
(Figures 6B and S6A). Moreover, a substantial fraction of
pre-existing enhancers remained active in B cells (60%)
but decreased in megakaryocyte-erythroid progenitors
(MEPs), erythroid cells (Erys), and T cells (30%) (Figures
6B and S6A). In contrast, activated de novo enhancers
were essentially restricted to the myeloid compartment
with 25%–28% being decorated with H3K27Ac in CMPs
andGMPs and40% inGns andMFs,whileHSCs andmul-
tipotent progenitors (MPPs) showed lower percentages (7%
and 14%) andMEPs, Erys, and B and Tcells were essentially
negative (Figures 6C and S6A). Similar trendswere observed
for pre-existing and de novo enhancers marked with
H3K4Me1 (Figure S6B). Heatmaps of the two enhancer
types during the transition from short-term hematopoietic
stem cells (ST-HSCs) to macrophages (Figure 6D) were
remarkably similar to those of pre-B cells transdifferentiat-
ing into macrophages (see Figure 5A). In contrast, the two
enhancer types were not activated in T cells (Figure 6E).
These findings are illustrated for the pre-existing 14-kb
URE enhancer of Pu.1 and the 88-kb putative enhancer of
Cebpb (Figure 6F), which are bound by PU.1 (Figure 1G).
A de novo enhancer is exemplified by the 65-kb enhancer
of Cebpb (Figure 6F). Strikingly, mRNA levels of genes asso-
ciated with pre-existing and de novo enhancers reflected
enhancer activity during hematopoiesis using two inde-
pendently derived datasets analyzed by either RNA-seq or
expression arrays (Figures 6G, S6C, and S6D; Lara-Astiaso
et al., 2014; Di Tullio et al., 2011). The arrays also showed
that in normal macrophages the expression levels of genes
associated with the two enhancer types nearly converged
(Figure S6D).
In conclusion, our data show that the majority of pre-
existing enhancers targeted by C/EBPa during transdiffer-
entiation are broadly active in hematopoietic stem cells,
progenitors, and B cells, whereas de novo enhancers are
largely restricted to the myeloid compartment.
The Activity of the Two Enhancer Types Reflect Pu.1,
Cebpa, and Cebpb Expression during Hematopoiesis
How are the two enhancer types observed during C/EBPa-
induced transdifferentiation controlled during normal
hematopoiesis? To study this we analyzed the expression
of Pu.1, Cebpa, and Cebpb during hematopoietic dif-
ferentiation. Pu.1 expression was found to closely correlate
with that of pre-existing enhancers, Pu.1 being broadlyhors
Figure 5. Kinetics of Histone Marks,
P300 Binding, and Gene Expression Asso-
ciated with Myeloid Enhancers
(A) Heatmaps visualizing H3K4Me1,
H3K27Ac, P300 binding, and H3K27Me3 at
pre-existing and de novo enhancers at
different hpi of induced C10 cells. Window,
6,000 bp; bin, 100. See also Figure S5A.
(B) Quantification of H3K4Me1, H3K27Ac,
and P300, as in (A). Bins with the highest
coverage are shown.
(C) Quantification of H3K27Me3, as in (A),
except values at the center position are
shown. See also Figure S5B.
(D) Screenshots of selected enhancers
showing C/EBPa, PU.1, P300, H3K4Me1,
H3K27Ac, and H3K27Me3 profiles in C10
cells. See also Figure S5C.
(E and F) Distribution of mRNA levels of
upregulated genes nearest to either pre-
existing (n = 318) or de novo (n = 103)
enhancers during transdifferentiation of
C10 cells and primary pre-B cells is shown.
See also Figures S5D and S5E.expressed in stem andprogenitor cells andweakly in Tcells,
MEPs, and Erys (Figure 7A). Similar expression patterns
were observed at the protein level with PU.1 reporter
mice (Back et al., 2005). In turn, Cebpa was expressed
mostly in the myeloid compartment where its levels were
highest in GMPs (Figure 7A; Wo¨lfler et al., 2010), in agree-
ment with the fact that mice lacking C/EBPa do not
develop GMPs (Zhang et al., 2004). In contrast, Cebpb
expression reached highest levels in macrophages andStem CGns (Figure 7A), suggesting that C/EBPb takes over the
role of C/EBPa in terminally differentiated myeloid cells.
This interpretation agrees with the fact that macrophages
from C/EBPb-knockout mice have functional defects
(Chen et al., 1997; Tanaka et al., 1995).
To test whether the Cebpa expression pattern reflects its
binding specificity in the hematopoietic system, we
analyzed the C/EBPa-binding sites identified in pre-exist-
ing and de novo enhancers in stem and progenitors cellsell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The Authors 241
Figure 6. Distribution of Active Myeloid
Enhancers during Hematopoietic Differ-
entiation
(A) Cartoon depicting blood cell lineage
specification.
(B and C) Percentage of pre-existing and de
novo macrophage enhancers intersecting
with enhancers decorated with H3K27Ac in
different hematopoietic progenitors and
differentiated cell types. The size of the
circles relative to circles in (A) indicates the
percentage of representation. See also Fig-
ures S6A and S6B.
(D) Heatmaps visualizing H3K27Ac and
H3K4Me1 decoration at pre-existing and
de novo enhancers during myeloid differ-
entiation. Window, 6,000 bp; bin, 100.
(E) As in (D), but for T cells.
(F) Screenshots of H3K4Me1 and H3K27Ac
profiles at selected C/EBPa-bound en-
hancers of Pu.1 and Cebpb in the indicated
hematopoietic cell types.
(G) Median mRNA levels of genes nearest
either pre-existing (green lines; n = 318) or
de novo (red lines; n = 103) enhancers in
different hematopoietic stem/progenitors
and differentiated cells. Statistical analysis
by Wilcoxon rank-sum test, **p < 0.001. See
also Figures S6C and S6D.and GMPs, as previously reported (Hasemann et al., 2014).
Strikingly, <10% of prospective myeloid enhancers were
bound by C/EBPa in the progenitors, while 80% of the
sites were bound in GMPs and in primary macrophages
(Figure 7B). C/EBPa binding in progenitor cells and pri-242 Stem Cell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The Autmary MF is illustrated for the PU.1 and Cebpb genes (Fig-
ure 7C) as well as for the Tlr4 and Ctsd genes.
Together, our observations indicate that, within the
hematopoietic system, the combination of Pu.1, Cebpa,
and Cebpb determines the activity of the two types ofhors
Figure 7. Expression Kinetics of Genes
Associated with Pre-existing and De Novo
Enhancers during Hematopoiesis
(A) mRNA levels of Pu.1, Cebpa, and Cebpb
in different hematopoietic stem/progenitor
cell types, based on RNA-seq data (Lara-
Astiaso et al., 2014).
(B) Percentages of pre-existing or de novo
enhancers bound by C/EBPa in early he-
matopoietic progenitors (Lin- Sca-1+ Kit+,
LSK cells), GMPs, or primary MF.
(C) Screenshots of C/EBPa bound to
selected enhancers of Pu.1, Cebpb, Tlr4, and
Ctsd in the indicated hematopoietic cell
types. Pre-ex., pre-existing.
(D) Pre-existing and de novo myeloid en-
hancers in pre-B cells and iMF, showing
PU.1 occupancy, binding sites targeted
by incoming C/EBPa (curved arrows),
enhancer states, and gene expression. Nu-
cleosomes are indicated by light blue balls.
(E) Artist’s rendering of the trajectory of
activated pre-existing enhancers within the
hematopoietic lineage tree (in green) and
de novo enhancers (in red). The arrow de-
picts how C/EBPa short circuits the two
trajectories when expressed in pre-B cells.prospective macrophage enhancers and, hence, the ex-
pression of adjacent genes in a manner that recapitulates
C/EBPa-induced transdifferentiation.DISCUSSION
Our study of C/EBPa-induced pre-B-cell-to-macrophage
transdifferentiation has revealed two types of prospective
myeloid enhancers that are activated by C/EBPa. Pre-exist-
ing enhancers in pre-B cells are decorated with active
enhancer marks and bound in their majority by PU.1,
while de novo enhancers are free of enhancer activation
marks and free of PU.1; C/EBPa simultaneously hyper-acti-
vates pre-existing enhancers and newly activates de novoStem Cenhancers (summarized in Figure 7D). These enhancers
drive a substantial part of the gene repertoire required for
the formation of functional macrophages. Strikingly, we
also observed a similar synergy between pre-existing and
de novo enhancers during myeloid lineage specification
during normal hematopoiesis (Figure 7E).
The finding that pre-existing-type myeloid enhancers
drive low-level expression of adjacent myeloid-restricted
genes in early hematopoietic progenitors provides a mech-
anistic explanation for the phenomenon dubbed ‘‘lineage
priming’’ (Hu et al., 1997). The observed expression of
the myeloid markers lysozyme and CSF-1 receptor in he-
matopoietic stem cells (Mossadegh-Keller et al., 2013; Ye
et al., 2003) supports this interpretation. The following ob-
servations indicate that PU.1 is a key component in theell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The Authors 243
generation of pre-existingmyeloid enhancers: (1)most pre-
existing enhancers are bound by the factor; (2) PU.1 is ex-
pressed in stem and progenitor cells, but downregulated
in T cells and Erys (Back et al., 2005; Lara-Astiaso et al.,
2014; Nutt et al., 2005), and this strongly correlates with
the distribution of pre-existing myeloid enhancers and
the expression of nearby genes; and (3) overexpression of
PU.1 in fibroblasts partially activates myeloid genes associ-
ated with pre-existing enhancers (Figure 2G) and C/EBPa
further enhances their expression, while C/EBPa alone
has no effect (Feng et al., 2008).
However, it is likely that, in addition to PU.1, other TFs
participate in the initiation of the establishment of pre-ex-
isting enhancers and the activation of de novo enhancers.
Thus, C/EBPa sites also were enriched for the RUNXmotif,
in line with the finding that during myelopoiesis Runx1
binds transiently to the URE element of the Pu.1 gene to
establish open chromatin, permitting the binding of PU.1
(Hoogenkamp et al., 2009). In addition, it is possible that
the Fos gene acts as a downstream effector, as it is directly
regulated by C/EBPa and we observed enrichment of
AP-1 motifs in C/EBP-bound sites where it might co-oper-
ate with C/EBPs.
The weakly active pre-existing myeloid enhancers in
hematopoietic progenitors appear to be in a stand-by
state that can be fully activated by changes in the bone
marrow microenvironment either during development
or in adult life, such as after infections with pathogens.
These signals may in turn increase the levels of PU.1,
C/EBPa, and C/EBPb expression. Thus, for example, bacte-
ria or inflammatory stimuli can upregulate Pu.1 expres-
sion in hematopoietic stem cells through the activation
of M-CSF, a cytokine that in turn activates the CSF-1 re-
ceptor (Mossadegh-Keller et al., 2013). In addition, the
yeast Candida albicans can induce emergency granulopoi-
esis in hematopoietic progenitors through upregulation of
C/EBPb (Hirai et al., 2006). Therefore, the ectopic expres-
sion of C/EBPa/b to induce transdifferentiation of pre-B
cells might mimic processes that are normally triggered
in hematopoietic progenitors by developmental cues or
pathogens.
Surprisingly, a subset of pre-existing enhancers appears
to be bi-functional. In B cells this subset is bound by
the B cell TF Ebf1, typically in combination with PU.1,
resulting in low-level expression. Binding of C/EBPa
further activates these genes, raising the possibility that
their products are themselves bi-functional. The Cebpb
gene illustrates this scenario as its putative 88-kb up-
stream enhancer is bound by Ebf1, which is eventually
replaced by C/EBPa during the conversion into myeloid
cells. In addition the factor is required for the function
of both B cells and macrophages (Chen et al., 1997;
Tanaka et al., 1995). However, whether the 88-kb site is244 Stem Cell Reports j Vol. 5 j 232–247 j August 11, 2015 j ª2015 The Autthe physiologically most relevant Cebpb enhancer is
unknown.
Previous work on TF combinations that induce cell fate
conversions have postulated two alternative models as fol-
lows: (1) a symmetric collaboration between various TFs
acting as pioneer factors, exemplified by Oct4, Sox2, and
Klf4 that act during iPSC reprogramming (Soufi et al.,
2012); and (2) a hierarchical model, exemplified by Ascl1
acting as a pioneer for the subsequent binding of Brn2
and Myt1l during induced neuronal transdifferentiation
(Wapinski et al., 2013). Here we propose a mixed model,
where the key lineage-instructive factors exert dual roles
as both pioneer and secondary factors. The conclusion
that C/EBPa can act as a pioneer factor is based on the
observation that it binds to chromatin regions free of acti-
vating histone marks and to a nucleosome-dense region
within de novo enhancers, agreeing with the reported
pioneer activity of C/EBPb (Siersbæk et al., 2011). It is
possible that PU.1 also can act as a pioneer factor, as it is
one of the earliest lineage-instructive factors expressed in
the hematopoietic system (Dzierzak and Speck, 2008),
and on its own can induce the expression of myeloid genes
in non-hematopoietic cells.
In conclusion, our work revealed that the collaboration
between an exogenous and an endogenous lineage-instruc-
tive TF (C/EBPa and PU.1) leads to the activation of pre-
existing and de novo myeloid enhancers during transdif-
ferentiation, resulting in macrophage differentiation.
Interestingly, this mechanism recapitulates the way endog-
enous C/EBP factors and PU.1 collaborate to induce
myeloid differentiation during normal hematopoiesis. It
will be interesting to determine whether conversions of
other cell types driven by TFs likewise recapitulate develop-
mental processes that result from the superimposition of
complementary enhancer types.EXPERIMENTAL PROCEDURES
Cell Culture, Retroviruses, and shRNA Constructs
The origin of the HAFTL pre-B cell line, its derivatives C10
(C/EBPaER-GFP) and C11 (C/EBPaER-hCD4), and induction of
transdifferentiation (treatment with 100 uM b-est and grown in
the presence of 10 nM Il-3 and 10 nM CSF-1) have been described
previously (Bussmann et al., 2009; Xie et al., 2004). The shC/
EBPb-KD07 directed to the ORF of Cebpb was purchased from
Sigma (Mission shRNA System) in a pLKO.1-puro lentiviral
backbone. An shRNA against PU.1 cloned into LMP-GFP virus
(Open Biosystems) was a gift from Dr. M. Sieweke (Sarrazin et al.,
2009). The 3T3 cell culture conditions and the PU.1-GFP construct
have been described previously (Feng et al., 2008). Phagocytosis of
yeast was performed as described previously by Rapino et al.
(2013). To test for statistical differences of C/EBPa binding after
knockdown of PU.1, we applied the Student’s t test, one-tailed,
alpha level (0.05).hors
FACS
FACS experiments were performed as described previously (Buss-
mann et al., 2009) using conjugated antibodies against Cd19
(550992) and Cd11b (552850) and combined with blocking anti-
body (553142) from BD Pharmingen. Unstained cells or an isotype
control antibody (553932, BD Pharmingen) were used as a nega-
tive control.ChIP, ChIP-Seq, and MNase-Seq Experiments
ChIP experiments were performed as described previously (van
Oevelen et al., 2008). DNA libraries were prepared using Illumina’s
reagents and instructions. Nucleosome positioning was deter-
mined by MNase digestion using a modification of a published
method (Cappabianca et al., 1999). All libraries were sequenced
on the Illumina GA IIx or Hiseq2000 sequencer.Processing of ChIP-Seq and MNase-Seq Data
High-throughput Illumina sequencing data were base-called using
the Illumina pipeline, and sequencing reads were aligned to the
mouse genome (mm9) using either the Illumina Eland alignment
tool or Bowtie (Langmead et al., 2009) without mismatches.
Aligned sequences were filtered to remove identical sequence
tags and sequence tags not aligning uniquely to the mouse
genome. To detect enriched regions, we used HOMER (http://
homer.salk.edu/homer/ngs/index.html) (Heinz et al., 2010; and
see Table S1). See the Supplemental Experimental Procedures for
further details. To test for statistical differences in the level or
reduction of coverage between sets of regions, we applied the Wil-
coxon rank-sum test, two-tailed, alpha level (0.05).Binding Site Annotation, Motif Analysis, and Gene
Expression
Position of non-redundant regions relative to TSS of nearest
gene (RefSeq mm9) was based on center position and calculated
by in-house Perl scripts. For a subset of genes, the median ex-
pression level was calculated, and, to test for statistical differences
in gene expression levels between sets of genes, we applied the
Wilcoxon rank-sum test, two-tailed, alpha level (0.05). Gene
expression values in hematopoietic cells (Lara-Astiaso et al.,
2014) were normalized by dividing each presented mRNA value
by the average mRNA of all listed genes per cell type. To annotate
genes for enrichment of GO terms, we employed David with
standard settings (Huang da et al., 2009). Motif discovery within
selected regions was performed using HOMER (Heinz et al.,
2010).Gene Expression Analyses by qRT-PCR
To analyze mRNA levels of selected genes in either C10 cells
induced with b-est or 3T3 cells overexpressing PU.1, we extracted
RNA using trizol and reverse transcribed it with GeneAmp RNA
PCR (Applied Biosystems). SybrGreen PCR Master Mix (Applied
Biosystems) was used for amplification and detection of cDNAs,
and PCR reactions were carried out with the AB7900HT detection
system (Applied Biosystems). To test for statistical differences
in mRNA levels, we applied the Student’s t test, one-tailed, alpha
level (0.05).Stem CACCESSION NUMBERS
The accessionnumbers for the ChIP-seq data reported in this paper
are GEO: GSE53173, GSE53362, and GSE53460 for chromatin
marks, factor binding, and MNase, respectively.
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Supplemental Information includes Supplemental Experimental
Procedures, six figures, four tables, and one movie and can be
found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2015.06.007.
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